Reuters logo
BRIEF-Sangamo says receives rare pediatric disease designation from FDA for SB-318
February 27, 2017 / 1:47 PM / 7 months ago

BRIEF-Sangamo says receives rare pediatric disease designation from FDA for SB-318

Feb 27 (Reuters) - Sangamo Therapeutics Inc

* Sangamo therapeutics receives rare pediatric disease designation from fda for sb-318 in vivo genome editing therapeutic for mps i

* Sangamo therapeutics inc - in 2017, co is conducting a phase 1/2 clinical trial evaluating sb-318 for mps i

* Sangamo therapeutics-submitted application to fda for odd,rare pediatric disease designation for sb-913;co’s in vivo genome editing program for mps ii Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below